EHA 2017 | Using vaccines to impart a long-term response in lenalidomide-treated MM

Ivan Borrello

Ivan Marques Borrello, MD, from the John Hopkins School of Medicine, Baltimore, MD, USA, describes the potential of applying vaccines following chemotherapy to impart a long-term therapeutic response in patients with multiple myeloma (MM). One such vaccine, GVAX, will soon undergo a randomised trial in combination with lenalidomide, compared to lenalidomide alone, on patients with MM who are undergoing a lenalidomide regimen. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter